What is it? IGHV (CLL) is a molecular test that determines the mutational status of the IGHV (Immunoglobulin Heavy Chain Variable Region) gene in patients with Chronic Lymphocytic Leukemia (CLL).
IGHV is part of the B-cell receptor, and its mutational status is one of the important biological characteristics of CLL.
What does it analyze? The test determines whether the IGHV gene in leukemic cells is:
This distinction helps characterize the biological profile of the disease.
Why is it important? IGHV status has prognostic significance in CLL. In general, patients with mutated IGHV have a less aggressive biological profile compared with patients with unmutated IGHV. The information obtained from this test may help the hematologist with:
When is it recommended? The test may be recommended for patients diagnosed with CLL, particularly during the initial assessment of the biological and prognostic profile of the disease.
The result should not be interpreted on its own. It is evaluated together with clinical data, hematological analyses, and other prognostic and molecular markers.
How is the test performed? The test analyzes the genetic material of leukemic cells to determine the mutational status of IGHV. The sample may be obtained from peripheral blood, depending on the clinical indication and laboratory protocol.
What does the result show? The result reports the IGHV status as: Mutated IGHV or Unmutated IGHV. This information provides the hematologist with important information about the biology of CLL and is used together with other factors to assess the patient.
